Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/54196
Title: Cellular characterization of artemisinin resistance in human malaria.
Authors: Low, Kum Yong.
Keywords: DRNTU::Science::Biological sciences::Molecular biology
Issue Date: 2013
Abstract: Malaria is a deadly disease transmitted by the Anopheles mosquito, and Plasmodium falciparum results in upwards of 1.5 million deaths per year. It is a disease endemic to tropical and sub-tropical regions. While chloroquine was effective during the 1960s to 1970s, the worldwide spread of chloroquine resistance has all rendered the drug useless against malaria, except in some areas. The introduction of artemisinins, from the Chinese herb Artemisia annua, in the 1970s proved highly effective against malaria, but in the past decade, there have been increasing reports of malarial resistance against artemisinin. This is a worrying trend as artemisinins and its derivatives are currently the most effective anti-malarial against the disease, and if resistance becomes prevalent, there will be no effective therapy against malaria. This study has studied the resistance characteristics of an in vitro artemisinin-resistant strain of P. falciparum. The resistant strain exhibits a 100-fold higher IC50 value as compared to the negative control. The resistant strain also exhibits significant resistance to artesunate (14-fold increase), but not to dihydroartemisinin (5-fold increase). It is also observed that the strain is not cross-resistant to chloroquine, mefloquine, quinine and pyrimethamine.
URI: http://hdl.handle.net/10356/54196
Rights: Nanyang Technological University
Fulltext Permission: restricted
Fulltext Availability: With Fulltext
Appears in Collections:SBS Student Reports (FYP/IA/PA/PI)

Files in This Item:
File Description SizeFormat 
FYP Report Final.pdf
  Restricted Access
540.23 kBAdobe PDFView/Open

Page view(s) 50

365
Updated on Dec 5, 2021

Download(s)

11
Updated on Dec 5, 2021

Google ScholarTM

Check

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.